Xeris Pharmaceuticals XERS
$16.97 +$0.35 (+2.11%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $17.00 +0.18%
Open$16.61
Prev close$16.62
Day range$16.53 – $17.04
Volume2.86M
Market cap$3.10B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$107.23M+44.2% YoY
Operating profit$16.92M+151.4% YoY
Net profit$11.29M+1,718.0% YoY
Diluted EPS$0.06
Free cash flow$35.31M+92.3% YoY
Operating cash flow$35.47M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin87.4%
Operating margin12.7%
Net margin-1.8%
Return on equity-27.1%
Return on assets-1.6%
Return on invested capital6.0%
Current ratio2.15
Liabilities / assets88.5%
Cash & investments$131.08M
Total debt$219.72M
Net cash (debt)-$88.64M
Free cash flow / sales19.7%
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $107.23M | $92.10M | $83.13M | $291.85M | $85.81M |
| Total Operating Revenue | $107.23M | $92.10M | $83.13M | $291.85M | $85.81M |
| Cost of Revenue | $12.43M | $12.51M | $10.57M | $42.57M | $10.95M |
| Gross Profit | $94.80M | $79.59M | $72.55M | $249.28M | $74.86M |
| Operating Expense | $77.88M | $74.42M | $64.64M | $224.38M | $58.09M |
| Selling and Admin Expenses | $64.11M | $61.04M | $53.14M | $182.37M | $47.50M |
| Research & Development | $11.06M | $10.67M | $8.78M | $31.17M | $7.87M |
| Depreciation & Amortization & Depletion | $2.71M | $2.71M | $2.71M | $10.84M | $2.71M |
| -Depreciation & Amortization | $2.71M | $2.71M | $2.71M | $10.84M | $2.71M |
| Operating Profit | $16.92M | $5.17M | $7.92M | $24.90M | $16.77M |
| Net Non-Operating Interest Income (Expense) | -$5.63M | -$5.49M | -$5.68M | -$24.34M | -$5.69M |
| Non-Operating Interest Income | $827,000.00 | $1.46M | $1.20M | $4.74M | $1.46M |
| Non-Operating Interest Expense | $6.46M | $6.95M | $6.88M | $29.08M | $7.15M |
| Special Income (Charges) | $0.00 | -$30.78M | – | $0.00 | $0.00 |
| Pretax Profit | $11.29M | -$31.10M | $2.23M | $554,000.00 | $11.08M |
| Tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Profit | $11.29M | -$31.10M | $2.23M | $554,000.00 | $11.08M |
| Profit from Continuing Operations | $11.29M | -$31.10M | $2.23M | $554,000.00 | $11.08M |
| Net Income to Parent Company | $11.29M | -$31.10M | $2.23M | $554,000.00 | $11.08M |
| Net Income to Common Stockholders | $11.29M | -$31.10M | $2.23M | $554,000.00 | $11.08M |
| Basic EPS | $0.06 | -$0.18 | $0.01 | $0.00 | $0.07 |
| Diluted EPS | $0.06 | -$0.18 | $0.01 | $0.00 | $0.06 |
| Other Income (Expense) | – | -$30.78M | – | – | – |
| -Less:Other Special Charges | – | $30.78M | – | – | – |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $423.22M | $411.91M | $392.01M | $383.53M | $383.53M |
| Total Current Assets | $289.27M | $274.76M | $251.68M | $240.31M | $240.31M |
| Cash and Cash Equivalents & Short-Term Investments | $131.08M | $121.75M | $111.75M | $111.04M | $111.04M |
| -Cash and Cash Equivalents | $131.08M | $121.75M | $111.75M | $111.04M | $111.04M |
| Receivables | $68.60M | $58.11M | $56.30M | $51.05M | $51.05M |
| -Accounts Receivable | $68.60M | $58.11M | $56.30M | $51.05M | $51.05M |
| Inventory | $76.93M | $80.93M | $74.23M | $68.67M | $68.67M |
| Other Current Assets | $12.66M | $13.98M | $9.40M | $9.55M | $9.55M |
| Total Non-Current Assets | $133.95M | $137.15M | $140.33M | $143.21M | $143.21M |
| Net PPE | $26.22M | $26.61M | $26.98M | $27.06M | $27.06M |
| -Gross PPE | $35.22M | $35.44M | $35.50M | $35.23M | $35.23M |
| -Accumulated Depreciation | -$9.00M | -$8.84M | -$8.51M | -$8.18M | -$8.18M |
| Goodwill and Other Intangible Assets | $102.81M | $105.52M | $108.23M | $110.94M | $110.94M |
| -Goodwill | $22.86M | $22.86M | $22.86M | $22.86M | $22.86M |
| -Other Intangible Assets | $79.95M | $82.66M | $85.37M | $88.08M | $88.08M |
| Other Non-Current Assets | $4.93M | $5.03M | $5.12M | $5.22M | $5.22M |
| Total Liabilities | $374.44M | $421.64M | $379.00M | $369.84M | $369.84M |
| Total Current Liabilities | $134.48M | $189.57M | $118.59M | $109.57M | $109.57M |
| Payables | $8.04M | $9.34M | $11.47M | $3.08M | $3.08M |
| -Accounts Payable | $8.04M | $9.34M | $11.47M | $3.08M | $3.08M |
| Current Accrued Expenses | $64.90M | $59.23M | $59.05M | $52.35M | $52.35M |
| Short-Term Debt and Capital Lease Obligation | $6.35M | $70.09M | $6.27M | $6.23M | $6.23M |
| -Current Capital Lease Obligation | $6.35M | $6.31M | $6.27M | $6.23M | $6.23M |
| Current Provisions | $17.67M | $18.60M | $18.72M | $18.97M | $18.97M |
| Other Current Liabilities | $4.02M | $4.98M | $4.35M | $4.89M | $4.89M |
| Total Non-Current Liabilities | $239.96M | $232.07M | $260.41M | $260.26M | $260.26M |
| Long Term Debt and Capital Lease Obligation | $219.72M | $219.35M | $252.28M | $251.87M | $251.87M |
| -Long Term Debt | $189.71M | $188.81M | $221.22M | $220.34M | $220.34M |
| -Long Term Capital Lease Obligation | $30.00M | $30.54M | $31.06M | $31.53M | $31.53M |
| Other Non-Current Liabilities | $20.24M | $12.72M | $8.13M | $8.40M | $8.40M |
| Total Equity | $48.78M | -$9.73M | $13.01M | $13.69M | $13.69M |
| Stockholders' Equity | $48.78M | -$9.73M | $13.01M | $13.69M | $13.69M |
| Capital Stock | $19,000.00 | $18,000.00 | $18,000.00 | $17,000.00 | $17,000.00 |
| -Common Stock | $19,000.00 | $18,000.00 | $18,000.00 | $17,000.00 | $17,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $737.66M | $690.43M | $682.09M | $685.00M | $685.00M |
| Retained Earnings | -$688.88M | -$700.17M | -$669.07M | -$671.31M | -$671.31M |
| Gains/Losses Not Affecting Retained Earnings | -$11,000.00 | -$10,000.00 | -$24,000.00 | -$25,000.00 | -$25,000.00 |
| -Current Debt | – | $63.78M | – | – | – |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $35.47M | $8.26M | $9.87M | $28.63M | $20.04M |
| Net cash flow from continuing operations | $35.47M | $8.26M | $9.87M | $28.63M | $20.04M |
| Net Income from Continuing Operations | $11.29M | -$31.10M | $2.23M | $554,000.00 | $11.08M |
| Gain/Loss from Continuing Operations | $0.00 | – | – | – | – |
| Depreciation & Depletion & Amortization | $3.22M | $3.21M | $3.21M | $12.69M | $3.20M |
| Other Non-Cash Items | $906,000.00 | $907,000.00 | $889,000.00 | $3.37M | $866,000.00 |
| Change in Working Capital | $9.25M | -$6.60M | -$603,000.00 | -$10.36M | -$373,000.00 |
| -Change in Receivables | -$10.49M | -$1.81M | -$5.25M | -$10.64M | $2.70M |
| -Change in Inventory | $2.70M | -$9.50M | $851,000.00 | -$19.29M | -$4.01M |
| -Change in Prepaid Assets | $1.33M | -$4.49M | $145,000.00 | -$2.10M | $1.25M |
| -Change in Payables and Accrued Expense | $15.61M | $4.82M | $9.01M | $19.62M | -$1.98M |
| -Change in Other Current Liabilities | -$499,000.00 | -$477,000.00 | -$434,000.00 | -$1.58M | -$422,000.00 |
| -Change In Other Working Capital | $602,000.00 | $4.85M | -$4.93M | $3.61M | $2.09M |
| Net cash flow from investing | -$159,000.00 | -$209,000.00 | -$325,000.00 | -$696,000.00 | -$333,000.00 |
| Net Cash Flow from Continuing Investing Activities | -$159,000.00 | -$209,000.00 | -$325,000.00 | -$696,000.00 | -$333,000.00 |
| Capital Expenditure | -$159,000.00 | -$209,000.00 | -$325,000.00 | -$696,000.00 | -$333,000.00 |
| Financing Cash Flow | -$25.98M | $1.94M | -$8.84M | $11.39M | -$266,000.00 |
| Net Cash Flow from Continuing Financing Activities | -$25.98M | $1.94M | -$8.84M | $11.39M | -$266,000.00 |
| Net Common Stock Issuance | -$752,000.00 | $409,000.00 | -$9.68M | -$1.71M | -$1.54M |
| Proceeds from Stock Option Exercised | -$2.15M | $1.53M | $847,000.00 | $13.10M | $1.27M |
| Ending Cash Balance | $135.10M | $125.77M | $115.77M | $115.06M | $115.06M |
| Net Change in Cash | $9.34M | $10.00M | $708,000.00 | $39.32M | $19.44M |
| Beginning Cash Balance | $125.77M | $115.77M | $115.06M | $75.74M | $95.62M |
| Free Cash Flow | $35.31M | $8.05M | $9.55M | $27.93M | $19.71M |
| Deferred Tax | – | – | – | $0.00 | $0.00 |
| Net Investment Purchase and Sale | – | – | – | $0.00 | $0.00 |
| Net Issuance Payments Of Debt | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on XERS.
Sign in to join the discussion.